Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience.

Autor: F McGowan P; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., D Hyter S; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Cui W; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Plummer RM; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Godwin AK; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Zhang D; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Jazyk: angličtina
Zdroj: International journal of laboratory hematology [Int J Lab Hematol] 2022 Feb; Vol. 44 (1), pp. 118-126. Date of Electronic Publication: 2021 Sep 29.
DOI: 10.1111/ijlh.13711
Abstrakt: Introduction: Monitoring patients with acute myeloid leukemia can be implemented through various techniques such as multiparameter flow cytometry, real-time quantitative polymerase chain reaction, and next-generation sequencing. However, there is scarce studies when comparing the data of next-generation sequencing and flow cytometry for monitoring disease progression, particularly how they might supplement one another when used in tandem.
Methods: We investigated 107 patients via retrospective analysis using follow-up MFC and NGS data with a total of 717 MFC and 247 NGS studies to compare these methods in monitoring minimal/measurable residual disease.
Results: 197 instances were MFC + /NGS + , 3 were MFC - /NGS - , 44 were MFC - /NGS + , and 3 are MFC + /NGS - . The majority of the MFC - /NGS + cases occurred within 6 months during the post-treatment phase (64%). Among 44 MFC - /NGS + instances, 13 had similar NGS profiles to their original day 0 diagnosis. The remaining cases showed preleukemic clonal hematopoiesis mutations, "likely pathogenic mutations," or "variants of uncertain significance."
Conclusion: Our findings show that flow cytometry has its advantages with comparable sensitivity in detecting minimal/measurable residual disease. Next-generation sequencing could be used in an increased and more regular capacity in conjunction with flow cytometry to achieve a more comprehensive surveillance of these patients, resulting in improved outcomes.
(© 2021 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje